Clinical Trial Update: Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating dendritic cell vaccines targeting Her2/Her3 in combination with pembrolizumab for brain metastases arising from triple-negat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Dendritic Cell Vaccine (Her2/Her3)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Status: RECRUITING